Real-life data on pasireotide in monotherapy or combined in active Cushing's disease.

ABSTRACT:

Introduction

In the last few years, the use of medical treatment in Cushing's disease (CD) has increased thanks to the availability of new molecules. Nevertheless, real-life data on combination treatments are still lacking.

Methods

This is a retrospective monocentric study evaluating the real-life efficacy and safety of pasireotide alone or when combined with cabergoline or metyrapone.

Results

A total of 18 patients (94% women; median age, 45 years) with active CD received pasireotide (median, 8 months), followed by a combination treatment (median, 22 months) with either cabergoline (2/9) or metyrapone (7/9) for half of the patients. Pasireotide alone significantly reduced urinary free cortisol (UFC) and late-night salivary cortisol (LNSC) (p < 0.01), achieving

SUBMITTER: Mondin A 

PROVIDER: S-EPMC12657153 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature